Evaluation of efficacy of subendometrial Gh injection for FET cycle of RIF patients

Evaluation of efficacy of subendometrial Growth hormone injection for FET cycle of RIF patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002576N30

Enrollment

Registered

2023-08-30

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility of other origin

Interventions

Intervention 1: Intervention group": At the time of hysteroscopy in luteal phase under anesthesia, Gh will be injected in subendometrial area of endometrial cavity at four points with needle. Interven

Eligibility

Sex/Gender

Female

Age

20 Years to 44 Years

Inclusion criteria

Inclusion criteria: RIF patients Have good quality embryo Having signed informed consent

Exclusion criteria

Exclusion criteria: Severe male infertility BMI>30 Uncontrolled hypothyroidism User of corticosteroids User of glucose control agents CNS tumors Uterine malformations Cavity distorting lesion Severe endometriosis Liver disease Asherman syndrome

Design outcomes

Primary

Measure	Time frame
Increase of pregnancy rate. Timepoint: Two weeks after embryo transfer. Method of measurement: Bhcg titer.;Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: Heart beat activity in transvaginal sonogram.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026